Penny Stock Sutro Biopharma Cuts Costs, Refocuses Pipeline

On Thursday, Sutro Biopharma, Inc. STRO prioritized its antibody-drug conjugates (ADC) pipeline, including three wholly-owned preclinical programs in its next-generation ADC pipeline.Exatecan ADC targeting Tissue Factor, STRO-004, will enter the clinic in the second half of 2025.STRO-006: Sutro’s differentiated integrin beta-6 ADC will enter clinical development in 2026, aimed at multiple solid tumors.An IND for Sutro’s first wholly-owned dual-payload ADC is anticipated to be filed in 2027.Sutro expects ope ...